Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity

References

• Jacob ST, Crozier I, Fischer WA 2nd, et al. Ebola virus disease. nature reviews disease primers. Vol. 6, Springer US; 2020.
   Google Scholar
• Campion EW, Feldmann H, Sprecher A, et al. Ebola. N Engl J Med. 2020. DOI:10.1056/NEJMra1901594
   Web of Science ®Google Scholar
• Kuhn JH, Amarasinghe GK, Basler CF, et al. ICTV virus taxonomy profile: filoviridae. J Gen Virol. 2019;100(6):911–912.
   Web of Science ®Google Scholar
• Mylne A, et al. A comprehensive database of the geographic spread of past human ebola outbreaks. Sci Data. 2014;1(1):1–10.
   Web of Science ®Google Scholar
• Centers for Disease Control. History of ebola virus disease. https://www.cdc.gov/vhf/ebola/history/chronology.html [accessed 15 October 2020].
   Google Scholar
• Feldmann H, Sanchez A, Geisbert TW. Filoviridae: marburg and ebola viruses. in Fields Virology: Sixth Edition. 2013; DOI:10.1007/978-1-4612-3900-0_30
   Google Scholar
• Sanchez A, Trappier SG, Mahy BWJ, et al. The virion glycoproteins of ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U. S. A. (1996) doi:10.1073/pnas.93.8.3602.
   Google Scholar
• Mehedi M, Falzarano D, Seebach J, et al. A new ebola virus nonstructural glycoprotein expressed through RNA editing. Journal of Virology. 2011;85(11):5406–5414.
   PubMed Web of Science ®Google Scholar
• Zhu W, Banadyga L, Emeterio K, et al. The roles of ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development. Viruses. 2019;11(11):999.
   Web of Science ®Google Scholar
• Muhlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of marburg virus and ebola virus by using artificial replication systems. Journal of Virology. 1999;73(3):2333–2342.
   PubMed Web of Science ®Google Scholar
• Tchesnokov EP, Raeisimakiani P, Ngure M, et al. RNA-Dependent RNA Polymerase Complex of Ebola Virus. Sci Rep. 2018;8(1). DOI:10.1038/s41598-018-22328-3
   PubMedGoogle Scholar
• Bornholdt ZA, Noda T, Abelson D, et al. Structural rearrangement of ebola virus vp40 begets multiple functions in the virus life cycle. Cell. 2013;154(4):763–774..
   PubMed Web of Science ®Google Scholar
• Harty RN, Brown ME, Wang G, et al. A PPxY motif within the VP40 protein of ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl. Acad. Sci. U. S. A. (2000) doi:10.1073/pnas.250277297.
   Google Scholar
• Noda T, Sagara H, Suzuki E, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002;76(10):4855–4865.
   PubMed Web of Science ®Google Scholar
• Miller EH, Chandran K. Filovirus entry into cells – new insights. Curr Opin Virol. 2012;2(2):206–214.
   PubMed Web of Science ®Google Scholar
• Jangra RK, Mittler E, Chandran K. Chapter 19: Filovirus entry into susceptible cells. in Biology and Pathogenesis of Rhabdo- and Filoviruses. 2014; DOI:10.1142/9789814635349_0019
   Google Scholar
• Huang Y, Xu L, Sun Y, et al. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell. 2002;10(2):307–316.
   PubMed Web of Science ®Google Scholar
• Noda T, Halfmann P, Sagara H, et al. Regions in Ebola virus VP24 that are important for nucleocapsid formation. The Journal of Infectious Diseases. 2007;196(s2):S247-S250.
   PubMed Web of Science ®Google Scholar
• Hoenen T, Groseth A, Kolesnikova L, et al. Infection of naïve target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol. 2006;(14):7260–7264. DOI:10.1128/jvi.00051-06
   PubMed Web of Science ®Google Scholar
• Mateo M, Carbonnelle C, Martinez MJ, et al. Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication. . The Journal of Infectious Diseases. 2011;204(suppl_3):S892-S896.
   PubMed Web of Science ®Google Scholar
• Banadyga L, Hoenen T, Ambroggio X, et al. Ebola virus VP24 interacts with NP to facilitate nucleocapsid assembly and genome packaging. Sci Rep. 2017;7(1). DOI:10.1038/s41598-017-08167-8
   PubMedGoogle Scholar
• Watt A, Moukambi F, Banadyga L, et al. A novel life cycle modeling system for ebola virus shows a genome length-dependent role of VP24 in virus infectivity. Journal of Virology. 2014;88(18):10511–10524.
   PubMed Web of Science ®Google Scholar
• Cong Q, Pei J, Grishin NV. Predictive and comparative analysis of Ebolaviru proteins. Cell Cycle. 2015;14(17). DOI:10.1080/15384101.2015.1068472
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Adachi T, Adhikari NKJ, et al. New filovirus disease classification and nomenclature. Nature Rev Microbiol. 2019;17(5):261–263.
   PubMed Web of Science ®Google Scholar
• Team S, Branch SP, Division V, et al. Ebola haemorrhagic fever in sudan, 1976. Bull World Health Organ. 1978;56(2):247-270.
   Google Scholar
• Shoemaker T, MacNeil A, Balinandi S, et al. Reemerging sudan ebola virus disease in uganda, 2011. Emerg Infect Dis. 2012; DOI:10.3201/eid1809.111536..
   Web of Science ®Google Scholar
• Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008;4(11):e1000212.
   PubMed Web of Science ®Google Scholar
• Albariño CG, Shoemaker T, Khristova ML, et al. Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in uganda and the democratic republic of the congo in 2012. Virology. 2013;442(2):97–100.
   PubMed Web of Science ®Google Scholar
• Kratz T, Roddy P, Tshomba Oloma A, et al. Ebola virus disease outbreak in isiro, democratic republic of the congo, 2012: signs and symptoms, management and outcomes. PLoS One. 2015;10(6):e0129333.
   Web of Science ®Google Scholar
• Burk R, Bollinger L, Johnson JC, et al. Neglected filoviruses. FEMS Microbiology Reviews. 2016;40(4):494–519.
   PubMed Web of Science ®Google Scholar
• Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of ebola virus. Lancet. 1995;345(8960):1271–1274.
   PubMed Web of Science ®Google Scholar
• Formenty P, Hatz C, Le Guenno B, et al. Human infection due to ebola virus, subtype Côte d’Ivoire: clinical and biologic presentation. The Journal of Infectious Diseases. 1999;179(s1):S48-S53.
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet. 1990;335(8688):502–505.
   PubMed Web of Science ®Google Scholar
• Barrette RW, Metwally SA, Rowland JM, et al. Discovery of swine as a host for the reston ebolavirus. Science. 2009;325(5937):204–206.
   PubMed Web of Science ®Google Scholar
• Miranda MEG, Miranda NLJ. Reston ebolavirus in humans and animals in the philippines: a review. The Journal of Infectious Diseases. 2011;204(suppl_3):S757-S760.
   PubMed Web of Science ®Google Scholar
• Cantoni D, Hamlet A, Michaelis M, et al. risks posed by reston, the forgotten ebolavirus. mSphere. 2016;1(6). DOI:10.1128/msphere.00322-16
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Update: Filovirus infection in animal handlers. Morb. Mortal. Wkly. Report. 39: 221. 1990;
   PubMedGoogle Scholar
• Goldstein T, Anthony SJ, Gbakima A, et al. The discovery of bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. 2018; DOI:10.1038/s41564-018-0227-2.
   Web of Science ®Google Scholar
• Forbes KM, Webala PW, Jääskeläinen AJ, et al. Bombali virus in mops condylu bat, kenya. Emerg Infect Dis. 2019;25(5). DOI:10.3201/eid2505.181666
   Web of Science ®Google Scholar
• Haaskjold YL, Bolkan HA, Krogh KØ, et al. Clinical features of and risk factors for fatal Ebola virus disease, moyamba district, sierra leone, December 2014–February 2015. Emerging Infectious Diseases. 2016;22(9):1537–1544.
   PubMed Web of Science ®Google Scholar
• Ji YJ, Duan XZ, Gao XD, et al. Clinical presentations and outcomes of patients with ebola virus disease in freetown, sierra leone. Infect Dis Poverty. 2016;5(1). DOI:10.1186/s40249-016-0195-9
   PubMedGoogle Scholar
• Vernet M-A, Reynard S, Fizet A, et al. Clinical, virological, and biological parameters associated with outcomes of ebola virus infection in macenta, guinea. JCI Insight. 2017;2(6). DOI:10.1172/jci.insight.88864
   PubMed Web of Science ®Google Scholar
• Maganga GD, Kapetshi J, Berthet N, et al. Ebola virus disease in the democratic republic of congo. New England Journal of Medicine. 2014;371(22):2083–2091.
   PubMed Web of Science ®Google Scholar
• Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with ebola in sierra leone. N Engl J Med. 2014;371(22):2092–2100.
   PubMed Web of Science ®Google Scholar
• Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation of patients with ebola virus disease in conakry, guinea. New England Journal of Medicine. 2015;372(1):40–47.
   PubMed Web of Science ®Google Scholar
• Barry M, Traoré FA, Sako FB, et al. Ebola outbreak in conakry, guinea: epidemiological, clinical, and outcome features. Med Mal Infect. 2014;44(11–12):491–494.
   PubMed Web of Science ®Google Scholar
• Barry M, Toure A, Traore FA, et al. Clinical predictors of mortality in patients with ebola virus disease. Clinical Infectious Diseases. 2015;60(12):1821–1824.
   Web of Science ®Google Scholar
• Dallatomasina S, Crestani R, Sylvester Squire J, et al. Ebola outbreak in rural west africa: epidemiology, clinical features and outcomes. Trop Med Int Heal. 2015;20(4):448–454.
   PubMed Web of Science ®Google Scholar
• Lado M, Walker NF, Baker P, et al. Clinical features of patients isolated for suspected ebola virus disease at connaught hospital, freetown, sierra leone: a retrospective cohort study. The Lancet Infectious Diseases. 2015;15(9):1024–1033.
   PubMed Web of Science ®Google Scholar
• Yan T, Mu J, Qin E, et al. Clinical characteristics of 154 patients suspected of having ebola virus disease in the ebola holding center of jui government hospital in sierra leone during the 2014 ebola outbreak. Eur J Clin Microbiol Infect Dis. 2015;34(10):2089–2095.
   Web of Science ®Google Scholar
• Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in kikwit, democratic republic of the congo: clinical observations in 103 patients. The Journal of Infectious Diseases. 1999;179(s1):S1-S7.
   PubMed Web of Science ®Google Scholar
• McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. Journal of Infectious Diseases. 2014;210(4):558–566.
   PubMed Web of Science ®Google Scholar
• Velásquez GE, Aibana O, Ling, EJ, et al. Time from infection to disease and infectiousness for ebola virus disease, a systematic review. Clinl Infect Dis. 2015;61(7):1135–1140.
   PubMed Web of Science ®Google Scholar
• Martines RB, Ng DL, Greer PW, et al. Tissue and cellular tropism, pathology and pathogenesis of ebola and marburg viruses. The Journal of Pathology. 2015;235(2):153–174.
   PubMed Web of Science ®Google Scholar
• Reynard S, Journeaux A, Gloaguen E, et al. Immune parameters and outcomes during Ebola virus disease. JCI Insight. 2019;4(1). DOI:10.1172/jci.insight.125106
   PubMed Web of Science ®Google Scholar
• Kerber R, Krumkamp R, Diallo B, et al. Analysis of diagnostic findings from the european mobile laboratory in guéckédou, guinea, March 2014 Through March 2015.Journal of Infectious Diseases. 2016;214(suppl 3):S250-S257.
   PubMed Web of Science ®Google Scholar
• Kerber R, Krumkamp R, Korva M, et al. Kinetics of soluble mediators of the host response in ebola virus disease. The Journal of Infectious Diseases. 2018;218(suppl_5):S496-S503.
   PubMed Web of Science ®Google Scholar
• Eisfeld AJ, Halfmann PJ, Wendler JP, et al. Multi-platform ’Omics analysis of human ebola virus disease pathogenesis. Cell Host Microbe. 2017;22(6):817–829.e8.
   PubMed Web of Science ®Google Scholar
• Villinger F, Rollin P, Brar S, et al. Markedly Elevated Levels of Interferon (IFN)-σ, IFN-α, Interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal ebola virus infection. The Journal of Infectious Diseases. 1999;179(s1):S188-S191.
   PubMed Web of Science ®Google Scholar
• Gupta M, Mahanty S, Ahmed R, et al. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1α and TNF-α and inhibit poly-IC-induced IFN-α in vitro. Virology. 2001;284(1):20–25.
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clinical & Experimental Immunology. 2002;128(1):163–168.
   PubMed Web of Science ®Google Scholar
• Wauquier N, Becquart P, Padilla C, et al. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4(10):e837.
   PubMed Web of Science ®Google Scholar
• Bixler SL, Goff AJ. The role of cytokines and chemokines in filovirus infection. Viruses. 2015;7(10):5489–5507.
   PubMed Web of Science ®Google Scholar
• Mandl JN, Feinberg MB Robust and sustained immune activation in human Ebola virus infection. Proc. Natl. Acad. Sci. U. S. A. (2015) doi:10.1073/pnas.1503864112.
   Google Scholar
• Ruibal P, Oestereich L, Lüdtke A, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533(7601):100–104.
   PubMed Web of Science ®Google Scholar
• Magrone T, Jirillo E. Sepsis: from historical aspects to novel vistas. Pathogenic and therapeutic considerations. Endocrine. Metab. Immune Disord. Drug Targets. 2019;19(4):490–502.
   Web of Science ®Google Scholar
• McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. U. S. A. (2015) doi:10.1073/pnas.1502619112.
   Google Scholar
• Sakabe S, Sullivan BM, Hartnett JN, et al. Analysis of CD8+ T cell response during the 2013–2016 Ebola epidemic in west africa. Proc. Natl. Acad. Sci. U. S. A. (2018) doi:10.1073/pnas.1806200115.
   Google Scholar
• LaVergne SM, Sakabe S, Kanneh L, et al. Ebola-Specific CD8+ and CD4+ T-Cell responses in sierra leonean ebola virus survivors with or without post-ebola sequelae. . The Journal of Infectious Diseases. 2020;222(9):1488–1497.
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5(4):423–426.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. . The American Journal of Pathology. 2003;163(6):2347–2370.
   Web of Science ®Google Scholar
• Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163(6):2371–2382.
   Web of Science ®Google Scholar
• Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. The International Journal of Biochemistry & Cell Biology. 2005;37(8):1560–1566.
   PubMed Web of Science ®Google Scholar
• Ebihara H, Rockx B, Marzi A, et al. Host response dynamics following lethal infection of rhesus macaques with zaire ebolavirus. The Journal of Infectious Diseases. 2011;204(suppl_3):S991-S999.
   PubMed Web of Science ®Google Scholar
• Warren T, Zumbrun E, Weidner JM, et al. Characterization of Ebola virus disease (EVD) in rhesus monkeys for development of EVD therapeutics. Viruses. 2020;12(1):92.
   PubMed Web of Science ®Google Scholar
• Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. The Journal of Infectious Diseases. 1999;179(s1):S199-S202.
   PubMed Web of Science ®Google Scholar
• Schnittler H-J, Feldmann H. Marburg and ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clinical Infectious Diseases. 1998;27(2):404–406.
   PubMed Web of Science ®Google Scholar
• Cross RW, Mire CE, Borisevich V, et al. The domestic ferret (mustela putorius fur) as a lethal infection model for 3 species ebolavirus. J Infect Dis. 2016;214(4):565–569.
   Web of Science ®Google Scholar
• Banadyga L, Dolan MA, Ebihara EH. Rodent-adapted filoviruses and the molecular basis of pathogenesis. J Mol Biol. 2016;428(17):3449–3466.
   PubMed Web of Science ®Google Scholar
• Yamaoka S, Banadyga L, Bray M, et al. Small animal models for studying filovirus pathogenesis. in Marburg- and Ebolaviruses.Current Topics in Microbiology and Immunology. 2017; DOI:10.1007/82_2017_9
   Google Scholar
• Bray M, Davis K, Geisbert T, et al. A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever. J Infect Dis. 1998;178(3):651–661.
   PubMed Web of Science ®Google Scholar
• Chan M, Leung A, Griffin BD, et al. Generation and characterization of a mouse-adapted makona variant of ebola virus. Viruses. 2019;11(11):987.
   Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. The Journal of Infectious Diseases. 1999;179(s1):S203-S217.
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Chepurnov AA, Volchkova VA, et al. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology. 2000;277(1):147–155.
   PubMed Web of Science ®Google Scholar
• Subbotina E, Dadaeva A, Kachko A, et al. Genetic factors of ebola virus virulence in guinea pigs. Virus Res. 2010;153(1):121–133.
   PubMed Web of Science ®Google Scholar
• Cross RW, Fenton KA, Geisbert JB, et al. Modeling the disease course of zaire ebolavirus infection in the outbred guinea pig. Journal of Infectious Diseases. 2015;212(suppl 2):S305-S315.
   PubMed Web of Science ®Google Scholar
• Gibb TR, Bray M, Geisbert TW, et al. Pathogenesis of experimental ebola zaire virus infection in BALB/c mice. J Comput Pathol. 2001;125(4):233–242.
   PubMed Web of Science ®Google Scholar
• Ebihara H, Zivcec M, Gardner D, et al. A syrian golden hamster model recapitulating ebola hemorrhagic fever. The Journal of Infectious Diseases. 2013;207(2):306–318.
   Web of Science ®Google Scholar
• Rasmussen AL, Okumura A, Ferris MT, et al. Host genetic diversity enables ebola hemorrhagic fever pathogenesis and resistance. Science. 2014;(6212):987–991. DOI:10.1126/science.1259595
   Web of Science ®Google Scholar
• Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. . Journal of General Virology. 2001;82(6):1365–1373.
   PubMed Web of Science ®Google Scholar
• Brannan JM, Froude JW, Prugar LI, et al. Interferon α/β receptor-deficient mice as a model for ebola virus disease. J Infect Dis. 2015;212(suppl 2):S282-S294.
   PubMed Web of Science ®Google Scholar
• Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. The Journal of Infectious Diseases. 2011;204(suppl_3):S986-S990.
   PubMed Web of Science ®Google Scholar
• Lüdtke A, Oestereich L, Ruibal P, et al. Ebola virus disease in mice with transplanted human hematopoietic stem cells. J Virol. 2015;89(8):4700–4704.
   PubMed Web of Science ®Google Scholar
• Bird BH, Spengler JR, Chakrabarti AK, et al. Humanized mouse model of Ebola virus disease mimics the immune responses in human disease. J Infect Dis. 2015; DOI:10.1093/infdis/jiv538.
   Web of Science ®Google Scholar
• Spengler JR, Prescott J, Feldmann H, et al. Human immune system mouse models of Ebola virus infection. Curr Opin Virol. 2017;25:90–96.
   PubMed Web of Science ®Google Scholar
• Spengler JR, Saturday G, Lavender KJ, et al. Severity of disease in humanized mice infected with ebola virus or reston virus is associated with magnitude of early viral replication in liver. J Infect Dis. 2018;217(1):58–63.
   PubMed Web of Science ®Google Scholar
• Lavender KJ, Williamson BN, Saturday G, et al. Pathogenicity of ebola and marburg viruses is associated with differential activation of the myeloid compartment in humanized triple knockout-bone marrow, liver, and thymus mice. The Journal of Infectious Diseases. 2018;218(suppl_5):S409-S417.
   PubMed Web of Science ®Google Scholar
• Escudero-Pérez B, Rottstegge M, Lüdtke A, et al. Comparative pathogenesis of ebola virus and reston virus infection in humanized mice. JCI Insight. 2019;4(21). DOI:10.1172/jci.insight.126070.
   PubMed Web of Science ®Google Scholar
• Wozniak DM, Lavender KJ, Prescott J, et al. The utility of human immune system mice for high-containment viral hemorrhagic fever research. Vaccines (Basel). 2020;8(1):98.
   PubMed Web of Science ®Google Scholar
• Spengler JR, Lavender KJ, Martellaro C, et al. Ebola virus replication and disease without immunopathology in mice expressing transgenes to support human myeloid and lymphoid cell engraftment. J Infect Dis. 2016;214(suppl 3):S308-S318.
   PubMed Web of Science ®Google Scholar
• Basler CF, Wang X, Mühlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U. S. A. (2000) doi:10.1073/pnas.220398297.
   Google Scholar
• Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The ebola virus vp35 protein inhibits activation of interferon regulatory factor 3. Journal of Virology. 2003;77(14):7945–7956.
   Web of Science ®Google Scholar
• Cardenas WB, Loo YM, Gale M Jr, et al. Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling. J Virol. 2006;80(11):5168–5178..
   PubMed Web of Science ®Google Scholar
• Feng Z, Cerveny M, Yan Z, et al. The VP35 protein of ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. . Journal of Virology. 2007;81(1):182–192.
   Web of Science ®Google Scholar
• Schümann M, Gantke T, Ebola Virus ME. VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory Domain. J Virol. 2009;83(17):8993–8997.
   Web of Science ®Google Scholar
• Leung DW, Prins KC, Borek DM, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. . Nature Structural & Molecular Biology. 2010;17(2):165–172.
   PubMed Web of Science ®Google Scholar
• Leung DW, Prins KC, Basler CF, et al. Ebolavirus VP35 is a multifunctional virulence factor. Virulence. 2010;1(6):526–531.
   PubMedGoogle Scholar
• Luthra P, Ramanan P, Mire C, et al. Mutual antagonism between the ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe. 2013;14(1):74–84.
   PubMed Web of Science ®Google Scholar
• Bale S, Julien JP, Bornholdt ZA, et al. Ebolavirus VP35 Coats the Backbone of Double-Stranded RNA for Interferon Antagonism. J Virol. 2013;87(18):10385–10388.
   PubMed Web of Science ®Google Scholar
• Edwards MR, Liu G, Mire CE, et al. Differential regulation of interferon responses by ebola and marburg virus VP35 Proteins. Cell Rep. 2016;14(7):1632–1640.
   PubMed Web of Science ®Google Scholar
• Hartman AL, Bird BH, Towner JS, et al. Inhibition of IRF-3 Activation by VP35 Is Critical for the High Level of Virulence of Ebola Virus. J Virol. 2008;82(6):2699–2704.
   Web of Science ®Google Scholar
• Prins KC, Delpeut S, Leung DW, et al. Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea Pigs. . Journal of Virology. 2010;84(6):3004–3015.
   Web of Science ®Google Scholar
• Woolsey C, Menicucci AR, Cross RW, et al. A VP35 mutant ebola virus lacks virulence but can elicit protective immunity to wild-type virus challenge. Cell Rep. 2019;28(12):3032–3046.e6.
   PubMed Web of Science ®Google Scholar
• Reid SP, Leung LW, Hartman AL, et al. Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation. . Journal of Virology. 2006;80(11):5156–5167.
   Web of Science ®Google Scholar
• Reid SP, Valmas C, Martinez O, et al. Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 subfamily karyopherin α proteins with activated STAT1. Journal of Virology. 2007;81(24). DOI:10.1128/jvi.01097-07
   PubMed Web of Science ®Google Scholar
• Mateo M, Reid SP, Leung LW, et al. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. Journal of Virology. 2010;84(2):1169–1175.
   PubMed Web of Science ®Google Scholar
• Xu W, Edwards MR, Borek DM, et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014;16(2):187–200.
   Web of Science ®Google Scholar
• Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006;2(7):e73.
   Web of Science ®Google Scholar
• Mateo M, Carbonnelle C, Reynard O, et al. VP24 Is a molecular determinant of Ebola virus virulence in guinea pigs. The Journal of Infectious Diseases. 2011;204(suppl_3):S1011-S1020.
   PubMed Web of Science ®Google Scholar
• Cheresiz SV, Semenova EA, Chepurnov AA. Adapted Lethality: what We Can Learn from Guinea Pig-Adapted Ebola Virus Infection Model. Adv Virol. 2016;2016:1–14.
   PubMed Web of Science ®Google Scholar
• Yen B, Mulder LCF, Martinez O, et al. Molecular Basis for Ebolavirus VP35 Suppression of Human Dendritic Cell Maturation. J Virol. 2014;88(21):12500–12510.
   Web of Science ®Google Scholar
• Lubaki NM, Ilinykh P, Pietzsch C, et al. The lack of maturation of ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. Journal of Virology. 2013;87(13):7471–7485.
   PubMed Web of Science ®Google Scholar
• Lubaki NM, Younan P, Santos RI, et al. The ebola interferon inhibiting domains attenuate and dysregulate cell-mediated immune responses. PLoS Pathog. 2016;12(12):e1006031.
   PubMed Web of Science ®Google Scholar
• Ilinykh PA, Lubaki NM, Widen SG, et al. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. . Journal of Virology. 2015;89(15):7567–7583.
   PubMed Web of Science ®Google Scholar
• Bosio CM, Aman MJ, Grogan C, et al. Ebola and marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis. 2003;188(11):1630–1638.
   PubMed Web of Science ®Google Scholar
• Mahanty S, Hutchinson K, Agarwal S, et al. Cutting Edge: impairment of dendritic cells and adaptive immunity by ebola and lassa viruses. The Journal of Immunology. 2003;170(6):2797–2801.
   PubMed Web of Science ®Google Scholar
• Okumura A, Pitha PM, Yoshimura A, et al. Interaction between ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol. 2010;84(1):27–33.
   Web of Science ®Google Scholar
• Okumura A, Rasmussen AL, Halfmann P, et al. Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection. . Journal of Virology. 2015;89(20):10399–10406.
   PubMed Web of Science ®Google Scholar
• Wahl-Jensen V, Kurz S, Feldmann F, et al. Ebola virion attachment and entry into human Macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis. 2011;5(10):e1359.
   PubMed Web of Science ®Google Scholar
• Olejnik J, Forero A, Deflubé LR, et al. Ebolaviruses associated with differential pathogenicity induce distinct host responses in human macrophages. . Journal of Virology. 2017;91(11). DOI:10.1128/jvi.00179-17
   PubMed Web of Science ®Google Scholar
• Lai CY, Strange DP, Wong TAS, et al. Ebola virus glycoprotein induces an innate immune response in vivo via TLR4. Front Microbiol. 2017. DOI:10.3389/fmicb.2017.01571
   Web of Science ®Google Scholar
• Dolnik O, Volchkova V, Garten W, et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. Embo J. 2004;23(10):2175–2184.
   PubMed Web of Science ®Google Scholar
• Escudero-Pérez B, Volchkova VA, Dolnik O, et al. Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability. PLoS Pathog. 2014;10(11):e1004509.
   PubMed Web of Science ®Google Scholar
• Iampietro M, Santos RI, Lubaki NM, et al. Ebola virus shed glycoprotein triggers differentiation, infection, and death of monocytes through toll-like receptor 4 activation. The Journal of Infectious Diseases. 2018;218(suppl_5):S327-S334.
   PubMed Web of Science ®Google Scholar
• Younan P, Iampietro M, Nishida A, et al. Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm. MBio. 2017;8(5). DOI:10.1128/mBio.00845-17
   Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8(5):503–507.
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of ebola virus infection with a single complex adenovirus vector. . Clinical and Vaccine Immunology. 2010;17(4):572–581.
   PubMedGoogle Scholar
• Marzi A, Feldmann F, Hanley PW, et al. Delayed disease progression in cynomolgus macaques infected with ebola virus makona strain. Emerg Infect Dis. 2015;21(10):1777–1783.
   Web of Science ®Google Scholar
• Warfield KL, Dye JM, Wells JB, et al. Homologous and heterologous protection of nonhuman primates by ebola and sudan virus-Like particles. PLoS One. 2015;10(3):e0118881.
   Web of Science ®Google Scholar
• Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic fever. PLoS One. 2012;7(4):e36192.
   Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic ebolavirus species. PLoS Pathog. 2010;6(5):e1000904.
   Web of Science ®Google Scholar
• Falzarano D, Feldmann F, Grolla A, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus. J Infect Dis. 2011;204(suppl_3):S1082-S1089.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Marzi A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against bundibugyo ebolavirus. PLoS Neglected Tropical Diseases. 2013;7(12):e2600.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–7304.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of ebola virus and marburg virus infection: table 1.. J Infect Dis. 2015;212(suppl 2):S91-S97.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424(6949):681–684.
   Web of Science ®Google Scholar
• Reed DS, Lackemeyer MG, Garza NL, et al. Aerosol exposure to zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 2011;13(11):930–936.
   PubMed Web of Science ®Google Scholar
• Alfson KJ, Avena LE, Beadles MW, et al. Particle-to-PFU ratio of ebola virus influences disease course and survival in cynomolgus macaques. J Virol. 2015;89(13):6773–6781.
   PubMed Web of Science ®Google Scholar
• Alfson KJ, Avena L, Beadles M, et al. Intramuscular exposure of macaca fascicularis to low doses of low Passage- or cell culture-adapted sudan virus or ebola virus. Viruses. 2018;10(11):642.
   Web of Science ®Google Scholar
• Kozak R, He A, Kroeker A, et al. Ferrets infected with bundibugyo virus or ebola virus recapitulate important aspects of human filovirus disease. J Virol. 2016;90(20):9209–9223.
   Web of Science ®Google Scholar
• Kroeker A, He S, De La Vega M-A, et al. Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget. 2017;8(28):46262–46272.
   PubMedGoogle Scholar
• Gupta M, MacNeil A, Reed ZD, et al. Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus. Virology. 2012;423(2):119–124.
   PubMed Web of Science ®Google Scholar
• Zaki SR, Shieh W-J, Greer P, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. The Journal of Infectious Diseases. 1999;179(s1):S36-S47.
   PubMed Web of Science ®Google Scholar
• Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol. 1998. DOI:10.1007/978-3-642-59949-1_7
   Web of Science ®Google Scholar
• Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and d-dimer levels associated with fatal and nonfatal outcomes in humans infected with sudan ebola virus. The Journal of Infectious Diseases. 2007;196(s2):S364-S371.
   PubMed Web of Science ®Google Scholar
• Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. The Lancet Infectious Diseases. 2015;15(11):1292–1299.
   PubMed Web of Science ®Google Scholar
• Gupta M, Goldsmith CS, Metcalfe MG, et al. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo ebolavirus relative to Zaire ebolavirus. Virology. 2010;402(1):203–208.
   PubMed Web of Science ®Google Scholar
• Boehmann Y, Enterlein S, Randolf A, et al. A reconstituted replication and transcription system for ebola virus reston and comparison with ebola virus zaire. Virology. 2005;332(1):406–417.
   PubMed Web of Science ®Google Scholar
• Groseth A, Marzi A, Hoenen T, et al. The ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog. 2012;8(8):e1002847.
   PubMed Web of Science ®Google Scholar
• Groseth A, Feldmann H, Theriault S, et al. RNA polymerase i-driven minigenome system for ebola viruses. Journal of Virology. 2005;79(7):4425–4433.
   PubMed Web of Science ®Google Scholar
• Bosworth A, Dowall SD, Armstrong S, et al. Investigating the cellular transcriptomic response induced by the makona variant of ebola virus in differentiated THP-1 Cells. Viruses. 2019;11(11):1023.
   PubMed Web of Science ®Google Scholar
• Kash JC, Muhlberger E, Carter V, et al. Global suppression of the host antiviral response by ebola- and marburgviruses: increased antagonism of the type i interferon response is associated with enhanced virulence. Journal of Virology. 2006;80(6):3009–3020.
   Web of Science ®Google Scholar
• Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with sudan ebola virus. The Journal of Infectious Diseases. 2007;196(s2):S357-S363.
   PubMed Web of Science ®Google Scholar
• Xiang C, Young H, et al. Comparison of cellular gene expression in ebola-zaire and ebola-reston virus-infected primary human monocytes. . Nature Genetics. 1999;23(S3):82.
   Google Scholar
• Younan P, Ramanathan P, Graber J, et al. The toll-like receptor 4 antagonist eritoran protects mice from lethal filovirus challenge. MBio. 2017;8(2). DOI:10.1128/mBio.00226-17.
   Web of Science ®Google Scholar
• Dilley KA, Voorhies AA, Luthra P, et al. The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing. PLoS One. 2017;12(6):e0178717.
   Web of Science ®Google Scholar
• Guito JC, Albariño CG, Chakrabarti AK, et al. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system. Virology. 2017;501:147–165.
   PubMed Web of Science ®Google Scholar
• Kimberlina CR Bornholdt ZA, Li S, et al. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl. Acad. Sci. U. S. A. (2010) doi:10.1073/pnas.0910547107.
   Google Scholar
• Leung DW, Shabman RS, Farahbakhsh M, et al. Structural and functional characterization of reston ebola virus VP35 interferon inhibitory domain. Journal of Molecular Biology. 2010;399(3):347–357.
   PubMed Web of Science ®Google Scholar
• Schwarz TM, Edwards MR, Diederichs A, et al. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability. J Virol. 2017;91(4). DOI:10.1128/jvi.01715-16
   Web of Science ®Google Scholar
• Zhang APP, Bornholdt ZA, Liu T, et al. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 2012;8(2):e1002550.
   Web of Science ®Google Scholar
• Chakraborty S, Rao BJ, Asgeirsson B, et al. Correlating the ability of VP24 protein from ebola and marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods. F1000Res. 2014;3:265.
   Google Scholar
• Pappalardo M, Juliá M, Howard MJ, et al. Conserved differences in protein sequence determine the human pathogenicity of ebolaviruses. Scientific Reports. 2016;6(1). DOI:10.1038/srep23743
   Google Scholar
• De Wit E, Munster VJ, Metwally SA, et al. Assessment of rodents as animal models for reston ebolavirus. J Infect Dis. 2011;204(suppl_3):968–972.
   Web of Science ®Google Scholar
• Nehls J, Businger R, Hoffmann M, et al. Release of immunomodulatory ebola virus glycoprotein-containing microvesicles is suppressed by tetherin in a species-specific manner. Cell Rep. 2019;26(7):1841–1853.e6.
   PubMed Web of Science ®Google Scholar
• Holmes EC, Dudas G, Rambaut A, et al. The evolution of Ebola virus: insights from the 2013-2016 epidemic. Nature. 2016;538(7624):193–200.
   PubMed Web of Science ®Google Scholar
• Kugelman JR, Wiley MR, Mate S, et al. Monitoring of Ebola virus Makona evolution through establishment of advanced genomic capability in Liberia. Emerging Infectious Diseases. 2015;21(7):1135–1143.
   PubMed Web of Science ®Google Scholar
• Hoenen T, Safronetz D, Groseth A, et al. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science. 2015;348(6230):117–119.
   PubMed Web of Science ®Google Scholar
• Simon-Loriere E, Faye O, Faye O, et al. Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic. Nature. 2015;524(7563):102–104.
   PubMed Web of Science ®Google Scholar
• Park DJ, Dudas G, Wohl S, et al. Ebola virus epidemiology, transmission, and evolution during seven months in sierra leone. Cell. 2015;161(7):1516–1526.
   Web of Science ®Google Scholar
• Tong YG, Shi WF, Liu D, et al. Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature. 2015; DOI:10.1038/nature14490.
   Web of Science ®Google Scholar
• Diehl WE, Lin AE, Grubaugh ND, et al. Ebola virus glycoprotein with increased infectivity dominated the 2013–2016 Epidemic. Cell. 2016;167(4):1088–1098.e6.
   PubMed Web of Science ®Google Scholar
• Urbanowicz RA, McClure CP, Sakuntabhai A, et al. Human adaptation of ebola virus during the west african outbreak. Cell. 2016;167(4):1079–1087.e5.
   PubMed Web of Science ®Google Scholar
• Ladner JT, Wiley M, et al. Evolution and spread of ebola virus in liberia, 2014–2015. Cell Host Microbe. 2015;18(6):659–669.
   PubMed Web of Science ®Google Scholar
• Dietzel E, Schudt G, Krähling V, et al. Functional characterization of adaptive mutations during the west african ebola virus outbreak. J Virol. 2017;91(2). DOI:10.1128/jvi.01913-16
   Web of Science ®Google Scholar
• Olabode A, Gatherer D, Jiang X, et al. Identification of important amino acid replacements in the 2013-2016 Ebola virus outbreak. bioRxiv. 2016;2014:075168.
   Google Scholar
• Wang H, Shi Y, Song J, et al. Ebola viral glycoprotein bound to its endosomal receptor niemann-pick C1. Cell. 2016; DOI:10.1016/j.cell.2015.12.044.
   Web of Science ®Google Scholar
• Ueda MT, Kurosaki Y, Izumi T, et al. Functional mutations in spike glycoprotein of Zaire ebolavirus associated with an increase in infection efficiency. Genes Cells. 2017;22(2):148–159.
   Web of Science ®Google Scholar
• Wang MK, Lim SY, Lee SM, et al. Biochemical basis for increased activity of ebola glycoprotein in the 2013–16 Epidemic. Cell Host Microbe. 2017;21(3):367–375.
   Web of Science ®Google Scholar
• Maximilian Fels J, Robert H. Bortz III, Tanwee Alkutkar, Eva Mittler, View ORCID ProfileRohit K. Jangra, Jennifer S. Spence, V. O. P. C. A glycoprotein mutation that emerged during the 2013–2016 Ebola virus epidemic alters proteolysis and accelerates membrane fusion. bioRxiv. 2020. DOI:10.1101/2020.07.13.201863
   Google Scholar
• Wong G, He S, Leung A, et al. Naturally Occurring Single Mutations in Ebola Virus Observably Impact Infectivity. . Journal of Virology. 2018;93(1). DOI:10.1128/jvi.01098-18
   PubMed Web of Science ®Google Scholar
• Marzi A, Chadinah S, Haddock E, et al. Recently identified mutations in the ebola virus-makona genome do not alter pathogenicity in animal models. Cell Rep. 2018;23(6):1806–1816.
   PubMed Web of Science ®Google Scholar
• Smither SJ, Eastaugh L, Ngugi S, et al. Ebola virus makona shows reduced lethality in an immune-deficient mouse model. J Infect Dis. 2016;214(suppl 3):S268-S274.
   PubMed Web of Science ®Google Scholar
• Reisler RB, Yu C, Donofrio MJ, et al. Clinical laboratory values as early indicators of ebola virus infection in nonhuman primates. Emerging Infectious Diseases. 2017;23(8):1316–1324.
   PubMed Web of Science ®Google Scholar
• Versteeg K, Menicucci AR, Woolsey C, et al. Infection with the makona variant results in a delayed and distinct host immune response compared to previous ebola virus variants. Sci Rep. 2017;7(1). DOI:10.1038/s41598-017-09963-y
   Google Scholar
• Jankeel A, Menicucci AR, Woolsey C, et al. Early transcriptional changes within liver, adrenal gland, and lymphoid tissues significantly contribute to ebola virus pathogenesis in cynomolgus macaques. . Journal of Virology. 2020;94(11). DOI:10.1128/jvi.00250-20
   PubMed Web of Science ®Google Scholar
• Ivanov A, Ramanathan P, Parry C, et al. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cell Mol Life Sci. 2020;77(13):2579–2603.
   Web of Science ®Google Scholar
• Cross RW, Speranza E, Borisevich V, et al. Comparative transcriptomics in ebola makona-infected ferrets, nonhuman primates, and humans. The Journal of Infectious Diseases. 2018; DOI:10.1093/infdis/jiy455.
   Web of Science ®Google Scholar
• Wong G, Leung A, He S, et al. The makona variant of ebola virus is highly lethal to immunocompromised mice and immunocompetent ferrets. J Infect Dis. 2018; DOI:10.1093/infdis/jiy141.
   Web of Science ®Google Scholar